Drug Discovery News: Breaking Drug Discovery News, Comments and Articles. - Page: 4

02:09 EDT 30th July 2015 | BioPortfolio

Drug Discovery News - Page: 4Twitter RSS

Read the latest Drug Discovery News from around the world, updated every five minutes. Breaking stories from leading news and press agencies, bloggers and experts on Drug Discovery.

Search or Follow Our Drug Discovery - Page: 4 News…

If you are looking for more stories, you may wish to search our extensive news archives for relevant stories: Search for More Drug Discovery - Page: 4 News.
You can also follow our Drug Discovery - Page: 4 news stories on Twitter: @DiscoveryDrug

Showing "drug drug discovery discovery" News Articles 76 to 100 of 24,000+

Wednesday 29th July 2015

Harbor Village Urges South Florida Residents to Abstain from the Use of E Cigarettes

Harbor Village comments on Miami Herald’s recent article. Miami, FL (PRWEB) July 29, 2015 On July 26th the Miami Herald reported e-cigarette shops are anticipating testing regulations imposed by the FDA for nicotine laced liquid products. Their report says cigarette use has decreased recently to record lows, but use of electronic cigarettes have raised considerably. E-Cigarettes are particularl...

Gilead rises on higher than expected revenues and earning in second quarter

Gilead Sciences (NASDAQ:GILD) was trading about 3% higher this morning as the US pharmaceutical group reported higher than expected earnings in the second quarter. Gilead earned US$4.49 billion ($3.15 per share) against US$3.66 billion ($2.36 per sh...

Highland Therapeutics Announces Initiation of Pivotal Trial of HLD-200 in Pediatric ADHD Patients

Primary endpoint: Improvement in ADHD symptoms, vs. placebo, from 8AM to 8PM Highland Therapeutics Inc. (“Highland”), a pharmaceutical company, today announced that its wholly owned subsidiary, Ironshore Pharmaceuticals & Development, Inc. (“Ironshore”), has initiated enrolment in a pivotal study to assess the safety and ...

US 2014 prescription drug spend rose 12.6% on higher expenditure for new hepatitis C treatments - Report

A government survey has revealed American spending on prescription drug jumped 12.6% in 2014 to $305.1…

Clinigen pushing the pedal to the metal

Clinigen's (LON:CLIN) recent full year results showed a company pressing on the accelerator pedal, with buckets of further growth potential. Shares in the firm, which promises to deliver the right drug at the right time, are already  up over 3...

ResolutionMD® Medical Imaging Software First to Receive Certification for Web and Mobile Diagnosis in Korea

Calgary Scientific Inc., a company known for creating innovative technology for the medical industry and beyond, announced today that ResolutionMD® enterprise image-viewer is the first to receive certification from the Ministry of Food and Drug Safety (MFDS) in Korea for diagnosis using both web and mobile devices. This certification enables medical prac...

Navidea (NAVB) Note 07-29-15

NIH Grant for Rheumatoid Arthritis & Funds for Cervical Cancer & Alzheimer’s NIH Grant for Atherosclerotic Plaques with Mass General / Harvard Medical Navidea Continues Unlocking Manocept as a Disease-Modifying Drug Platform Download Full 12-Page Note with Important Disclosures: Morning Note 07-29-15 NAVB NOTE: On Thursday, July 30, 2015 at 8:30 am EDT, Navidea will hold their Q2 con...

Sanofi’s late stage drug trial for type 2 diabetes meets primary endpoint

French drug major Sanofi on Wednesday said the LixiLan-O phase III trial for its drug candidate to treat…

UPDATE: Sanofi’s late-stage drug trial for type 2 diabetes meets primary endpoint

French drug major Sanofi on Wednesday said the LixiLan-O phase III trial for its drug candidate to treat…

Certara Launches Its Simcyp In Vitro (Data) Analysis Toolkit to Improve Drug Discovery and Development Study Results

This new standalone solution is designed to meet the needs of early-stage drug discovery and development researchers Certara®, the global biosimulation technology-enabled drug development company, today announced the launch of its Simcyp In Vitro (Data) Analysis (SIVA) Toolkit, version 1.0. The SIVA Toolkit is designed to enable the analysis...

ArQule to Report Second Quarter 2015 Financial Results on August 5, 2015

ArQule, Inc. (Nasdaq: ARQL) announced that it will report its financial results for the second quarter 2015 before the market opens on Wednesday, August 5, 2015. The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and provide a general business update. The live webcast can be accessed in the...

Cardax Product Candidates Demonstrate Superior Bioavailability vs. Microalgal Astaxanthin in Monkey Study

Results Support Accelerated Product Launch Cardax, Inc. (“Cardax”) (OTCQB:CDXI) announced today that its astaxanthin consumer health candidates CDX-085 and ASTX-1F demonstrated more than two and one-half times higher oral bioavailability than a leading microalgal astaxanthin product in a head-to-head monkey study. The study was conducted by top-tie...

Sisters-in-Arms Unite to Battle Transvaginal Mesh (TVM) Misinformation and Pending Judicial Countdown

Victims desire to bring shadow sufferers out of their self-imposed silence and seek solutions In what has taken shape as a classic sister solidarity story, three female strangers, united by sickness, have joined forces to educate hundreds of thousands of women across the United States who continue to suffer in silence from their trans-vaginal mesh (TVM...

Morning Read: CMS report on national health spending shows big increase in drug prices, FDA pushing for better pharma quality metrics with new guidelines

CMS report on health spending points to escalating prescription drug prices as a significant factor, FDA releases draft guidance for advancing the quality and supply of medications.

Wednesday’s most followed in U.S. including Twitter, Citrix Systems, Garmin, Akamai Technologies, Gilead Sciences, GlaxoSmithKline, Altria, Anthem, Hilton, Hess

U.S. shares moved higher ahead of the statement from the Federal Reserve’s policy-setting meeting due to be released this afternoon. The S&P 500 (INDEXSP:.INX) added 0.6 percent to 2,105.45 at 11:42 a.m. in New York. The 30-company Dow Jone...

ARIAD to Receive up to $200 Million Through Iclusig Non-Dilutive Synthetic-Royalty Financing with PDL BioPharma

Funding to support initiation of first-line study of brigatinib in ALK+ NSCLC and commercial launch readiness for brigatinib ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will receive $100 million in cash – $50 million upon deal execution late yesterday and an additional $50 million in one year – through a synt...

Cellular Research Introduces Whole Transcriptome Single Cell Precise Assays

Cellular Research, Inc., today announced an early access program for its new Whole Transcriptome Single Cell Precise™ Assays, which enable absolute and direct molecular counting of the entire transcriptome from single cells without any specialized equipment or training. “Recent technological advances have enabled the analysis of gene expressio...

Acceleron Pharma to Host Second Quarter 2015 Financial Results Conference Call and Webcast on August 6, 2015

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced that the Company will host a conference call and live webcast on Thursday, August 6, 2015, at 8:00 AM (EDT) to report second qua...

Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI)

MI3 Alert for Combination Products Review Process from Initiative for Patient Centered Innovation (iPCI) Madison, NJ (PRWEB) July 29, 2015 The third Medical Innovation Impact Index (MI3) Alert considers FDA processes for the review and approval of combination products, in particular, drug/device combinations. The current system received a score of 0 (range -10 to +10) for its impact on medical in...

HKS / FreemanWhite: Designing the Future of Healthcare

JACKSONVILLE, Fla., July 29, 2015 /PRNewswire/ -- HKS and FreemanWhite, a Haskell Company, have been selected as the design team for the new Baptist MD Anderson Cancer Center in Jacksonville. This project represents a healthcare milestone – the opportunity to transform cancer care and provide advanced treatment options to adult patients locally, regionally, nationally and internationall...

New FDA-Approved Device For Treatment Of Drug-Resistant Epilepsy Now Offering Hope To Patients In U.S.

HOUSTON, July 29, 2015 /PRNewswire/ -- In just one month following FDA approval of the AspireSR® generator for the VNS Therapy® System, leading hospitals across approximately 40 states have begun providing this new treatment option for patients with drug-resistant epilepsy. As many as one third of people with epilepsy experience seizures that persist in spite of treatment with antie...

CSSi LifeSciences™ and PRC Clinical Join Forces to Offer Extended Clinical Trial Services

GLEN BURNIE, Md., July 29, 2015 /PRNewswire/ -- CSSi LifeSciences™ formalized a strategic partnership agreement with PRC Clinical, a Silicon Valley-based CRO specializing in Clinical Trial Management. CSSi LifeSciences™ is specialized in strategic, marketing, and regulatory consulting, FDA advisory services, and patient recruitment services. The core expertise of PRC Clinical is focuse...

GlaxoSmithKline Q2 beats despite Advair hit, lower margins

LONDON, July 29 (Reuters) - A further slide in sales of lung drug Advair and lower profit margins following a business overhaul hit GlaxoSmithKline in the second quarter, although core earnings per share fell by a less-than-expected 9 percent.

Evogene Announces Discovery and Validation of Novel Plant Targets for Herbicides

- Newly discovered targets predicted to represent new modes of action - Evogene Ltd. (NYSE; TASE:EVGN), a leading company for the improvement of crop productivity and economics for the food and feed industries, announced today the discovery and successful validation in plants of the first set of novel plant targets, representing a key milestone in its ...

CHMP Backs Antifungal Isavuconazole (Cresemba)

The triazole antifungal is indicated for treatment of adults with invasive aspergillosis and mucormycosis in patients for whom amphotericin B is not appropriate. Orphan Drug Approvals



Advertisement
 
Advertisement
 

News Quicklinks